Spruce Biosciences Q2 FY26 net loss widens to $16.23 million; R&D expenses rise to $12.16 million - SPRB News | RalliesSpruce Biosciences Q2 FY26 net loss widens to $16.23 million; R&D expenses rise to $12.16 million
S
SPRB• Program timeline and study plans
- TA-ERT BLA submission for MPS IIIB remains targeted for Q4 2026; accelerated approval path seeks CSF HS-NRE as surrogate endpoint.
- TrAnsform confirmatory study, plus an expanded access program, are both expected to start in Q4 2026; advocacy groups invested USD 5.5 million.
Quarterly results and cash position
- Spruce Biosciences posted a Q2 net loss of USD 16.2 million, or USD 6.68 per share.
- Cash and cash equivalents climbed to USD 96.3 million at June 30, from USD 48.9 million at Dec. 31.
- R&D expense totaled USD 12.2 million; operating expenses reached USD 16.5 million, including USD 0.9 million in stock-based compensation.
